A groundbreaking therapy capable of postponing the onset of type 1 diabetes for up to three years is set to be made available on the NHS, heralding a new era in diabetes care. The National Institute for Health and Care Excellence (NICE) has approved teplizumab—also known as Tzield and developed by Sanofi—as the first treatment that directly targets the immune system’s attack on insulin-producing cells.
Teplizumab is authorized for use in children aged eight and older as well as adults diagnosed in the early, pre-symptomatic stages of type 1 diabetes. With approximately 400,000 people in the UK living with the condition, this therapy offers hope for delaying a lifelong and demanding illness.
Administered as a one-time treatment over 14 consecutive days via intravenous infusion, teplizumab reprograms the immune system to halt the destruction of pancreatic cells. Clinical evidence demonstrates that this delay can extend the symptom-free period by nearly three years, giving patients crucial additional time before intensive insulin management begins.
READ MORE: Gloucestershire Schools to Close Amid Extreme Heat
NICE estimates that around 1,100 individuals will be eligible for this treatment in its first year on the NHS, with roughly 820 eligible annually thereafter. Dr Elizabeth Robertson, Director of Research at Diabetes UK, describes the approval as “a landmark moment” that moves care beyond insulin and towards preventing the condition itself.
Early detection through screening is vital to maximize the benefits of teplizumab. Current UK studies such as the Early Surveillance for Autoimmune Diabetes (Elsa), focusing on children aged 2 to 17, and the T1DRA study, screening adults between 18 and 70, aim to identify type 1 diabetes before symptoms manifest.
Helen Knight, Director of Medicines Evaluation at NICE, highlighted: “This is a genuinely exciting recommendation that balances clinical benefit with value for taxpayers. It provides people diagnosed early precious extra time before facing the full demands of the disease.”
Families like that of nine-year-old Dima from Newbury—diagnosed through the Elsa study—already recognize the value. His mother, Elena Boichak, shared, “Teplizumab has given us time. Every month Dima can remain a child without the burdens of insulin injections is invaluable.”
Breakthrough T1D CEO Karen Addington called it “an incredible moment for the type 1 community,” emphasizing the profound impact of immunotherapy in delaying disease onset and transforming lives.
This historic approval signals a promising shift toward earlier intervention and improved outcomes for those at risk of type 1 diabetes in the UK.